PTI - Proteostasis Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.1200
-0.0400 (-1.27%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.1600
Open3.1500
Bid3.16 x 2200
Ask3.40 x 3200
Day's Range3.0200 - 3.1600
52 Week Range1.7100 - 10.3800
Volume492,970
Avg. Volume1,443,432
Market Cap153.374M
Beta (3Y Monthly)-0.86
PE Ratio (TTM)N/A
EPS (TTM)-1.75
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.80
Trade prices are not sourced from all markets
  • ACCESSWIRElast month

    These 4 Biotech Stocks Are Raising Eyebrows

    CORAL GABLES, FL / ACCESSWIRE / December 21, 2018 / The biotech industry is based on a framework made up of cunning edge medical technologies designed with the patient's best interests at heart. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Proteostasis Therapeutics, Inc (PTI), Alta Mesa Resources, Inc (AMR), and Stemline Therapeutics, Inc (STML) are 4 biotech stocks worth taking a look at. Premier Health Group (OTC:PHGRF) (CSE:PHGI), as a company, recognizes the importance of meeting the demands and needs of its 100,000, and growing, active patient network.

  • Benzingalast month

    The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 20) • XBiotech Inc (NASDAQ: XBIT ) Down In The Dumps (Biotech ...

  • PR Newswirelast month

    Proteostasis Therapeutics Provides Clinical Enrollment Update

    BOSTON, Dec. 20, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today provided a clinical enrollment update.  The Company, while remaining blinded to data from the first cohort, now expects to report complete efficacy and safety data from the Phase 1, randomized, double-blind, placebo-controlled study of its proprietary combination therapy triplet (PTI-808, PTI-801, and PTI-428) and from the high-dose doublet study in subjects with CF in the first quarter of 2019. The Company previously planned to report preliminary results from the triplet study by dose cohort as each dose cohort was completed, beginning with a low-dose cohort.

  • How Many Insiders Bought Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Shares?
    Simply Wall St.last month

    How Many Insiders Bought Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Shares?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices Read More...

  • Implied Volatility Surging for Proteostasis Therapeutics (PTI) Stock Options
    Zackslast month

    Implied Volatility Surging for Proteostasis Therapeutics (PTI) Stock Options

    Proteostasis Therapeutics (PTI) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Waltham's Eloxx aims to reach cystic fibrosis patients that Vertex can't
    American City Business Journalslast month

    Waltham's Eloxx aims to reach cystic fibrosis patients that Vertex can't

    The Waltham startup is taking on the market giant Vertex Pharmaceuticals by developing an injection that targets the 10 percent of patients that Vertex and others haven't touched.

  • This Week's Top Tech Earnings and Today's Trending Stocks: PTI & NBEV
    Zackslast month

    This Week's Top Tech Earnings and Today's Trending Stocks: PTI & NBEV

    Ryan McQueeney discusses concerns about slowing economic growth in China and a major court ruling affecting healthcare stocks. He also highlights trending stocks Proteostasis Therapeutics and New Age Beverages. Later, he previews earnings from Red Hat, Oracle, and Micron.

  • Biotech News: Proteostasis Therapeutics (PTI) Stock Soars on Genentech
    InvestorPlacelast month

    Biotech News: Proteostasis Therapeutics (PTI) Stock Soars on Genentech

    The Boston, Mass.-based company said that it has reached an exclusive license agreement to offer the rights for a Genentech product–the company is part of the Roche Group. The product in question are therapeutic small molecule modulators designed to treat some form of cystic fibrosis with an undisclosed target to be integrated from the Proteostasis network. The deal does not include the cystic fibrosis transmembrane conductance regulator (CFTR) modulators and it has no connection to PTI’s investigational medicines or any of its other ongoing research programs linked to the ailment. “We are thrilled to enter into this agreement with Genentech, an industry leader with a proven record of success in small molecule research and development,” said Meenu Chhabra, who is the President and CEO of Proteostasis Therapeutics.

  • Benzingalast month

    Proteostasis Therapeutics Rallies On Genentech Licensing Agreement

    Proteostasis Therapeutics develops therapies for the treatment of cystic fibrosis, or CF, and other diseases and struck an agreement with Genentech for the rights to a potential therapeutic small molecule modulators of an undisclosed target within the Proteostasis Network. In exchange for the rights, Proteostasis will receive upfront milestone payments of more than $100 million from Genentech and tiered royalties on sales of future medicines from the license agreement. Proteostasis Therapeutics' new licensing agreement validates its network potential and could be seen as a sign that future agreements will arise, Cantor Fitzgerald's Elemer Piros said in a research report.

  • PR Newswirelast month

    Proteostasis Therapeutics Announces Global License Agreement with Genentech

    BOSTON, Dec. 17, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced a worldwide, exclusive license agreement with Genentech, a member of the Roche Group, for rights to potential therapeutic small molecule modulators of an undisclosed target within the proteostasis network.  The agreement does not include cystic fibrosis transmembrane conductance regulator (CFTR) modulators and is unrelated to PTI's investigational medicines or other ongoing research programs in cystic fibrosis. The proteostasis network consists of more than 1,000 proteins organized into pathways that can be regulated or targeted by drugs.

  • Vertex's (VRTX) Triple Combo Cystic Fibrosis Studies Succeed
    Zacks2 months ago

    Vertex's (VRTX) Triple Combo Cystic Fibrosis Studies Succeed

    Vertex's (VRTX) two phase III studies evaluating a triple combination regimen of VX-659 plus tezacaftor and ivacaftor meet the primary endpoint. Stock rises almost 5%.

  • PR Newswire2 months ago

    Proteostasis Therapeutics to Participate in Upcoming Investor Conferences

    BOSTON , Nov. 21, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to ...

  • Is the Options Market Predicting a Spike in Proteostasis Therapeutics (PTI) Stock?
    Zacks2 months ago

    Is the Options Market Predicting a Spike in Proteostasis Therapeutics (PTI) Stock?

    Investors need to pay close attention to Proteostasis Therapeutics (PTI) stock based on the movements in the options market lately.

  • Proteostasis Therapeutics (PTI) Reports Q3 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Proteostasis Therapeutics (PTI) Reports Q3 Loss, Tops Revenue Estimates

    Proteostasis (PTI) delivered earnings and revenue surprises of -8.70% and 27.88%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Will Proteostasis Therapeutics (PTI) Report Negative Earnings Next Week? What You Should Know
    Zacks2 months ago

    Will Proteostasis Therapeutics (PTI) Report Negative Earnings Next Week? What You Should Know

    Proteostasis (PTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire3 months ago

    Consolidated Research: 2018 Summary Expectations for Lexington Realty Trust, Proteostasis Therapeutics, PDC Energy, Twenty-First Century Fox, Square, and Sabra Healthcare REIT — Fundamental Analysis, Key Performance Indications

    NEW YORK, Oct. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • PR Newswire3 months ago

    Proteostasis Therapeutics Prices Public Offering of Common Stock

    BOSTON, Oct. 23, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, announced today that it has priced an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $6.75 per share. The gross proceeds to Proteostasis from the offering, before underwriting discounts and commissions and offering costs, are expected to be approximately $74.3 million.  Proteostasis has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of common stock. All of the shares to be sold in the offering are being sold by Proteostasis.

  • Benzinga3 months ago

    The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks None of the stocks hit 52-week highs in Monday's session. Down In The Dumps (Biotech stocks hitting 52-week ...

  • PR Newswire3 months ago

    Proteostasis Therapeutics Announces Proposed Public Offering of Common Stock

    BOSTON, Oct. 22, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, announced today that it intends to offer and sell, subject to market and other conditions, 9,000,000 shares of its common stock in an underwritten public offering. As part of this offering, Proteostasis intends to grant the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock.  All of the shares to be sold in the offering are to be sold by Proteostasis. Leerink Partners, Piper Jaffray & Co. and Cantor Fitzgerald & Co. are acting as joint book-running managers for the offering.

  • 5 Low-Priced Biotech Stocks to Take Advantage of the Market Rout
    InvestorPlace3 months ago

    5 Low-Priced Biotech Stocks to Take Advantage of the Market Rout

    As we recently mentioned, biotech stocks have been particularly hammered over the last few weeks. Unfortunately, that’s meant that many biotech stocks have been hit hard. The market rout has caused many biotech stocks to drop to single or low double-digit prices.

  • Why Proteostasis Therapeutics Tumbled 23.2% on Friday
    Motley Fool3 months ago

    Why Proteostasis Therapeutics Tumbled 23.2% on Friday

    Some investors booked profits following the company's recent cystic fibrosis trial data.

  • Simply Wall St.3 months ago

    Is Proteostasis Therapeutics Inc (NASDAQ:PTI) Worth US$10.35 Based On Intrinsic Value?

    In this article I am going to calculate the intrinsic value of Proteostasis Therapeutics Inc (NASDAQ:PTI) by taking the expected future cash flows and discounting them to today’s value. I Read More...

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Stocks to Watch: Proteostasis Therapeutics and Endocyte

    NEW YORK, NY / ACCESSWIRE / October 19, 2018 / Shares of biotech stocks Proteostasis Therapeutics and Endocyte were seeing big gains on different exciting announcements. Proteostasis announced encouraging preliminary results while traders learned that Endocyte will be purchased by Novartis for $2.1 billion. Proteostasis Therapeutics, Inc. shares closed up 447.62% on Thursday on skyrocket volume of about 94 million shares.

  • PTI Stock News: Why Is Proteostasis Therapeutics Stock Skyrocketing Today
    InvestorPlace3 months ago

    PTI Stock News: Why Is Proteostasis Therapeutics Stock Skyrocketing Today

    The preliminary clinical trial results sending PTI stock higher today concern Proteostasis Therapeutics’ (NASDAQ:PTI) therapies to treat cystic fibrosis and other dysfunctional protein processing diseases. The preliminary results are for tests involving PTI-808, PTI-801, and PTI-428. According to Proteostasis Therapeutics, the goal of its recent clinical trials is to determine the safety, tolerability, and pharmacokinetics of the three drugs.

  • Benzinga3 months ago

    Proteostasis Therapeutics Shares Surge On Positive Preliminary Cystic Fibrosis Trial Results

    Biotech Proteostasis Therapeutics Inc. (NASDAQ: PTI) develops therapeutics for the treatment of cystic fibrosis and associated disorders. Proteostasis shares were surging 300 percent on the announcement of positive preliminary results from three doublet cohorts of Phase 1 placebo-controlled studies in subjects with cystic fibrosis.